News Kiniksa Pharmaceuticals, Ltd.

Equities

KNSA

BMG5269C1010

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
16.91 ^USD	+0.18%		-2.20%	-3.59%

Apr. 03	Wedbush Adjusts Kiniksa Pharmaceuticals' PT to $30 From $28, Maintains Outperform Rating	MT
Apr. 02	Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024	Apr. 16	AQ
Wedbush Adjusts Kiniksa Pharmaceuticals' PT to $30 From $28, Maintains Outperform Rating	Apr. 03	MT
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart	Apr. 02	AQ
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart	Apr. 02	CI
PRACTICE STATEMENT LETTER PROPOSED SCHEME OF ARRANGEMENT IN RESPECT OF: KINIKSA PHARMACEUTICALS, LTD - Form 8-K	Mar. 29	PU
Kiniksa Pharmaceuticals' Q4 Earnings, Revenue Increase	Feb. 28	MT
Transcript : Kiniksa Pharmaceuticals, Ltd., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Reports Q4 Revenue $83.4M, vs. Street Est of $72.3M	Feb. 28	MT
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution	Feb. 28	AQ
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024	Feb. 21	AQ
Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for the Year 2024	Jan. 08	CI
Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 01:30 PM	Jan. 08
Kiniksa Pharmaceuticals Provides Corporate Update	Jan. 04	AQ
Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference	Jan. 02	AQ
Wedbush Lifts Kiniksa Pharmaceuticals' PT to $25 From $23 Ahead of Planned Q1 Reporting of Initial Data on KPL-404; Maintains Outperform Rating	Jan. 02	MT
Transcript : Kiniksa Pharmaceuticals, Ltd., Q3 2023 Earnings Call, Oct 31, 2023	23-10-31
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Reports Q3 Revenue $67M, vs. Street Est of $64.4M	23-10-31	MT
Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for 2023	23-10-31	CI
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kiniksa Pharmaceuticals, Ltd.

Equities

KNSA

BMG5269C1010

Summary

Filters